



A.forall joins forces with Nanoform and IMGA to advance innovative oncology treatment

Anderlecht, 16 October 2025

A.forall is proud to announce a new, strategic collaboration with **Nanoform Finland Plc**, a leading nanoparticle medicine enabling company and **IMGA Futurum Tech Fund**, the venture capital arm of Portugal's largest asset manager IMGA. Together, the three parties have established a new company: **BRAFMed Lda**, which will lead the development and commercialization of a nanoformulated version of **encorafenib**, a targeted oncology treatment currently marketed as Braftovi® (a registered trademark of Pfizer).

BRAFMed Lda will lead the clinical development, manufacturing and future outlicensing of **Nanoencorafenib**, a next-generation formulation using Nanoform's proprietary nanoparticle technology. The aim: to improve patient experience through a simplified, high-drugload, patient-centric treatment regimen.

Clinical trials and manufacturing of Nanoencorafenib will be carried out at Nanoform's facility in Helsinki. IMGA Futurum Tech Fund provides strategic investment and governance, while A.forall brings its expertise in generic and value-added medicine development, regulatory registration and commercialization to prepare the product for future partnerships.

*"This partnership reflects our belief in smart innovation and our drive to make impactful treatments more accessible," says **Steen Vangsgaard**, CEO of A.forall. "By combining development expertise with cutting-edge nanoformulation, we aim to create a product that is not only effective, but easier to use, improving patient experience and supporting healthcare professionals in the oncology field."*

The initial focus is on simplifying the current dosing regimen: while traditional formulations may require up to six capsules daily, the Nanoencorafenib prototype enables once-daily dosing with a single capsule. This has the potential to improve compliance, reduce pill burden and support treatment continuity in real-world settings.

A strategic fit with A.forall's value-added mission

This agreement is fully aligned with A.forall's strategy to expand its value-added generics portfolio through focused partnerships and targeted innovation. The company remains committed to Making Affordable Medicines Available to All, and sees innovation as a key lever in increasing access to value-added medicines.

"Value-added innovation plays a growing role in generic healthcare. We believe this partnership is a concrete step forward. Not just for A.forall, but for the broader mission of improving oncology care," says Vangsgaard.





About A.forall

A.forall is a Belgian pharmaceutical group fully dedicated to generics and value-added medicines. With headquarters in Anderlecht, offices in Ireland and the US, and distribution in over 60 countries, A.forall combines development expertise with global reach to make high-quality medicines more accessible. A.forall is a global player in the generics market, now with 35+ molecules on the European and US market and a fully stocked pipeline of mainly injectable generics and value-added products covering various therapeutic areas. A.forall is part of The Riverside Company's portfolio, a global investment firm focused on the smaller end of the middle market.

For more information, please visit www.aforallpharma.com

About Nanoform

Nanoform Finland Plc is a Nasdaq-listed technology company headquartered in Helsinki, Finland. Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products.

For more information, please visit www.nanoform.com

About IMGA Futurum Tech Fund

The IMGA Futurum Tech Fund is managed by IM Gestão de Ativos, Sociedade Gestora de Organismos de Investimento Coletivo, SA (IMGA). The fund focuses on investing in high-potential, innovative healthcare, life science and future tech ventures across Europe. Currently, IMGA is the largest independent asset manager in Portugal and a sector reference in the Iberian Peninsula, with a portfolio of more than 5 billion euros. Constantly seeking to adapt its product offering to clients' needs and different markets contexts, IMGA is expanding its activity in terms of products and services, its global reach and distribution channels, while maintaining its strategic vision and values.

For more information, please visit: www.imga.pt

We're happy to provide additional context or answer any questions you may have.

For media inquiries or more information, please contact:

A.forall Group NV
Communication Department
communications@aforallpharma.com
+32 2 526 64 14



www.aforallpharma.com



A.forall Group NV
Square Marie Curie 50
1070 Anderlecht - Belgium



Tel.: +32 2 526 64 10
info@aforallpharma.com
www.aforallpharma.com



VAT/CBE: (BE) 0684.777.042 (RLE Brussels)
IBAN: BE87 3631 7007 5594 (BIC: BBRUBEBB)